HEALTH-I-CARE

ECCMID 2019 Booth 1.93

Innovations for safer healthcare

Health-i-care is a unique cross border INTERREG project, combining knowledge from Dutch and German business, health and science partners to protect the public from infections and help combat antibiotic resistance.

www.health-i-care.eu

health-i-care 21 health-i-care

INDEX1. About the project2. Pipeline Corner: health-i-care3. BioVisible4. Checkbuster & Hycult Biotech5. OPHARDT Hygiene & Virtask B.V.- Anne4CAre6. Project overview & map7. Financiers & contact information

LEAD PARTNER:

IN COLLABORATION WITH :

ABOUT THE PROJECT Health-i-care focuses on the development ofinnovative products and technologies that protectthe public from infections and help combat antibi-otic resistance. Thirty innovation consortia havebeen established for the health-i-care project.

Each consortium consists of one small and medi-um-sized business (SME) and supporting partnersfrom knowledge institutions (e.g. universities)and the healthcare sector (e.g. hospitals). Theseconsortia develop demand-oriented innovationsthat are innovative and novel tools or resourceswithin the professional fields of medical informa-tion provision & training/eHealth, diagnostics& prevention, infection prevention - OneHealth,medical (e)-technology.

The 30 consortia present the progress and currentstatus of their innovations during biannual innova-tion fora,- followed by discussions on their innova-tions with the fora participants. This enables the entrepreneurs and consortia to adapt their innova-tion to the rapidly changing market situation that is typical in the areas of microbiology, hygiene and infection prevention. Various healthcare institutions in the Dutch and German project area will be used by the 30 innovation consortia as a ‘living lab’ for their innovations, where prototypes will be tested and optimised. Health-i-care uses cross-country and cross-sector network development to strengthen the innovative capacity of the border region and, consequently, the development of a unified region with sound health economics.

Monday 15 April, 12.15 - 13.15h, Arena 3HEALTH-I-CARE

is at

ECCMID 2019- on the exhibition floor, at booth 1.93- in the pipeline corner: health-i-care,

Mon. 15 April, 12.15 - 13.15h, Arena 3

Prof. Dr. Alex W. Friedrich, Chair and Head of the Department of Medical Microbiology and Infection Prevention at the University Medical Center Groningen

Kristin Klar, M.Ed., Research associate/doctoral student at the Institute of Medical Microbiology, Münster University Hospital (UKM)

Gastrointestinal and respiratory infections in childhood lead to health impairment, but also to absence from school. In this context, hand hygiene is the most important preventative measure. Foun-dations for infection-preventing behaviour should be laid as early as childhood. Currently, primary school children’s knowledge about factors relevant to hygiene is insufficiently known and there are no age-adapted soap dispensers with lasting moti-vating and educational effects. An interdisciplinary and translational approach to addressing these problems is presented.

Dr. Erik Toonen, R&D project leader at Hycult Biotech B.V.

EcHECk: diagnostic assay for serological detection of O157 EHEC infections.

Do you remember the 2011 outbreak in Germany due to EHEC infection in food? Do you know why infectious disease institutes are interested in a new test? Current diagnostic methods only detect 70% of the cases. Hycult Biotech and Radboud Univer-sity are offering a solution for complete detection called EcHECk with a wider range of detection and a test that can be reimbursed.

Dr. Michel E. van der Rest, CEO at BioVisible B.V.

BioVisible provides a point-of-care (POC) test to per-form a quick “on-site” assessment of possible health risks. Nucleic acid sequence based amplification (NASBA) in combination with a portable amplifi-cation and detection device allows for rapid RNA amplification. This enables viability detection and increased sensitivity of the test due to a high target number per cell (tmRNA 1000 copies per cell). Validation of “on-site” Legionella detection and My-cobacterium tuberculosis from patients discharged from a hospital after treatment is currently ongoing.

Prof. Dr. Heiman FL Wertheim, Head of the Medical Microbiology Department at Radboud University Medical Center

Immediately before a prostate biopsy, the patient is given an oral antibiotic to prevent infection. Due to increasing antibiotic resistance, we see infections occurring more frequently, despite this antibiotic prophylaxis. Screening patients for resistant bacte-ria before such an intervention may be a sensible strategy. For this purpose, Mediaproducts B.V. and Radboudumc have jointly developed selective cul-ture plates using different types of antibiotics. These are now being validated by several hospitals..

PIPELINE CORNER: HEALTH-I-CARE

Dr. Corinna Glasner, Scientific Project Manager health-i-careDepartment of Medical Microbiology and Infection Prevention at the University Medical Center Groningen

Innovations for safer healthcare in diagnostics & infection prevention from the Dutch-German

border region, the health-i-care example

PITCHES:

MODERATORS:

3 health-i-care health-i-care 4

BioVisible CONSORTIUM PARTNERS: • Christophorus-Kliniken Coesfeld• Universitair Medisch Centrum Groningen (UMCG)

Checkbuster CONSORTIUM PARTNERS: • Klinikum Leer• Universitair Medisch Centrum Groningen (UMCG)• Universiteit Twente (UT)

The cooperation between BioVisible (NL), UMCG (NL)and CKC (DE) is aimed at the development and commercialisation of a molecular diagnostic “Point of Care” test.

The consortium is currently developing isothermal Mycobacterium tuberculosis (MTB) and Legionella diagnostics using a portable NASBA amplification and detection system. Importantly, by using this technique, various multiple-drug resistant types of MTBs will be targeted.

The development of so-called accuspheres, freeze-dried trehalose pellets containing all ingredients, enables a diagnostic dual target test in a single tube.

CONTACT PERSON: Dr. Michel E. van der Rest, CEO

E-Mail: m.rest@biovisible.com www.biovisible.com

CONTACT PERSON: Gert-Jan Hemmers, CEO

E-Mail: gert-jan@checkbuster.comwww.checkbuster.com

The publication “Infectiepreventie in ziekenhuizen kan echt nog beter“ by the Dutch Healthcare Inspec-torate (May 2016) states clearly that “the worldwide increase in resistance of bacteria to more and more different antibiotics is a cause for great concern”.

Hygiene audits contribute to better infection preven-tion, while also helping to specifically focus on the importance of precautionary measures and guidelines. The Checkbuster consortium has devel-oped an audit application for tablets and smart-phones that will perform structured hygiene audits to meet quality objectives in hospitals and healthcare institutions (e.g. EurSafety Health-Net). The Check-buster platform is multilingual and enables a faster and more effective audit process. Its extensive dash-

EcHECk is the name of a new to develop rapid test for efficient and reliable detection of EHEC (entero-hemorragic Escherichia coli) infections. Contamina-tion with EHEC can lead to development of hemo-lytic uremic syndrome (HUS), a severe kidney disease.

The new diagnostic test is developed within a unique consortium with highly reputable HUS reference centra and experts in the area of EHEC infectious in Nijmegen and Groningen (the Netherlands) and Münster (Germany). The project is guided by Hycult Biotech, an SME specialized in the development of immunological tests for infectious diseases, in a close

Hycult Biotech CONSORTIUM PARTNERS: • Radboudumc• Universitätsklinikum Münster (UKM)

CONTACT PERSON: Loek Willems, Business Development Manager

E-Mail: l.willems@hycultbiotech.com www.hycultbiotech.com

board provides valuable management information, such as trends and improvement potentials.This ready-to-use product can be used by hospitals, nursing homes, GP practices, rehabilitation clinics and national health care offices, etc. The hygiene and infection-prevention staffs of the University Medical Centre Groningen and the Canisius Wilhelmina Hos-pital in Nijmegen were the first to gain experience with the use of Checkbuster.The completely new Checkbuster Pro platform was launched in October 2018. It is robust, safer and suit-able for much faster development in order to meet specific customer requirements or adapt to chang-ing regulations.

Checkbuster, inspect & report | share & prevent

collaboration with the Pediatric department of Rad-boudumc, Nijmegen.

Hycult Biotech has started with the development of a test that can detect antibodies to EHEC O157 in serum or plasma. Simultaneously Radboudumc has made steps forwards to discriminate between infection-mediated HUS and atypical or genetical HUS. The combined efforts should lead to a bigger window for screening of EHEC infections and should especially prevent the complications involved and enable possible interventions.

In addtition, the accusphere concept enables transport and storage at room temperature. These research objectives are of great importance because they will expand the applicability of the portable isothermal amplification platform by offering a multi-tude of commercial tests.

The combination of a diagnostic tool, which would be able to detect various targets with resistance phe-notypes and portable capability, will be of great value for point of care diagnostics and can contribute to public health in relation to fast detection of resistant and multiple resistant bacteria both in hospitalized patients and in interregional border crossings and thus prevent transmission of resistant bacteria.

HEALTH-I-CARE IS REPRESENTED AT ECCMID BY

THE FOLLOWING FIVE PARTNERS:

5 health-i-care

BIELEFELD

BRÜGGEN

COESFELD

BAD SALZUFLEN

BEEK UBBERGEN

OLDENBURG

GRONINGEN

AMERSFOORT

DEN HAAG

NIJMEGEN

MÜNSTER

HARFSEN

ISSUM

LEEUWARDEN

MÖNCHENGLADBACH

SCHORTENS

SNEEK

UDEN

WAGENINGEN

WARDENBURG

ZWOLLE

ENSCHEDE

HEERENVEEN

Partners in health-i-care

health-i-care 6

Innovations for safer healthcare

This consortium’s focus is on lasting improvement in infection protection in various age groups.

A sub-project is devoted to the promotion of hygiene awareness among children and adolescents. In this age group in particular, the topic of infection pre-vention plays a key role and sets the course for future hygiene behaviour. To this end, the consortium’s work includes the development of a motivational soap dispenser, which is intended to encourage hand hygiene and playfully teach the children the correct way to wash.

Another focus is the effective improvement of hand hygiene behaviour in old people’s homes and care

Anne, Charles’ personal assistant.

You know, I’m not as young as I used to be and I live on my own, but I can cope very well. It’s just that my memory sometimes lets me down. But now I’ve got Anne and she reminds me about everything - my appointments, my medication - and she even makes sure I eat well. Too bad she can’t cook, otherwise I would marry her! Charles tells about his personal virtual assistant, Anne. A friendly woman on a screen who listens, carries out assignments and speaks (in more than 10 languages). Information is transmitted through text, images, video

OPHARDT Hygiene CONSORTIUM PARTNERS: • Canisius Wilhelmina Ziekenhuis (CWZ)• Universitätsklinikum Münster (UKM)

Virtask B.V. - Anne4Care CONSORTIUM PARTNERS: • Canisius Wilhelmina Ziekenhuis (CWZ)• Universitair Medisch Centrum Groningen (UMCG)• Landeszentrum Gesundheit (LZG) NRW

CONTACT PERSON: Markus Marek, Marketing Strategist BU Medical

E-Mail: mmarek@ophardt.com www.ophardt.com

CONTACT PERSON: Annemarie Johannes, CEO

E-Mail: a.johannes@virtask.nl www.anne4care.nl/en

homes, particularly in order to protect immunocom-promised patients from infection. To this end, smart Wi-Fi enabled disinfectant dispensers record the hygiene behaviour in the participating institutions. Targeted interventions to improve compliance will be extrapolated and implemented based on the data.

The consortium comprises OPHARDT hygiene with consortium leader Dr. Siegfried Steltenkamp, Cani-sius Wilhelmina Hospital in Nijmegen under the project management of Prof. Dr. Andreas Voss and Münster University Hospital with the working group of Prof. Dr. Karsten Becker from the Institute of Medi-cal Microbiology.

and speech. In this way, people with disabilities such as impaired vision, hearing and hand functions and those with low literacy are given access to important information.

UMCG in Groningen, CWZ in Nijmegen and LZG NRW have jointly provided medical information on infec-tion prevention and the risk of antibiotic resistance. In addition, medication notifications promote im-proved therapy compliance.

So, Anne will make sure that appointments are not forgotten - for example with you, the doctor - and pro-mote medication therapy in a fun and accessible way!

by

This project is being carried out within the context of the INTERREG Programme Germany-Netherlands and is financially supported by the European Union and the following institutions:

CONTACT INFORMATION

UNIVERSITY MEDICAL CENTRE GRONINGEN (UMCG):Lead Partner

University Medical Centre GroningenHanzeplein 19713 GZ Groningen (NL)

Prof. Dr. Alex W. FriedrichHead of the Department of Medical Microbiology an Infection Prevention

Dr. Corinna GlasnerScientific Project Manager

c.glasner@umcg.nl

EUROHEALTHCONNECT (EHC):Management Office

eurohealthconnectPostbus 5457500 AM Enschede (NL)

Annette DwarsCEO

Antje WunderlichProject Coordinator

info@eurohealthconnect.eu

GERMAN-DUTCH CHAMBER OF COMMERCE (DNHK):Business Partner

Duits-Nederlandse HandelskamerNassauplein 302585EC Den Haag (NL)

Günter GülkerCEO

Gianna CorbelliHead of Trade Fair Department

Kiona JansenProject leader

k.jansen@dnhk.org

Innovations for safer healthcare

www.health-i-care.eu